Woodstock Corp Sells 2,385 Shares of Johnson & Johnson (NYSE:JNJ)

Woodstock Corp lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,068 shares of the company's stock after selling 2,385 shares during the quarter. Johnson & Johnson accounts for 1.3% of Woodstock Corp's investment portfolio, making the stock its 20th largest position. Woodstock Corp's holdings in Johnson & Johnson were worth $13,610,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $29,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $32,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $33,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $36,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

JNJ traded up $0.16 during trading hours on Monday, hitting $155.37. 6,665,172 shares of the stock were exchanged, compared to its average volume of 7,943,546. The stock has a 50-day simple moving average of $154.31 and a 200-day simple moving average of $153.66. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market cap of $373.83 billion, a price-to-earnings ratio of 23.36, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.